ARVCs with MVP had higher LV mass (93 vs. 75 g/m <sup>2</sup> , p = 0.02) and a higher prevalence of LV wall motion abnormalities (27% vs. 5%, p = 0.02) compared to ARVCs without valve abnormalities.<h4>Conclusions</h4>MVP is prevalent in ARVC and characterized by <i>PKP2</i> variants in most cases. This evidence concerns the gene PKP2 and arrhythmogenic right ventricular cardiomyopathy.